Medtech startup Nucs AI has raised $3.5 million Seed funding.
Founded in 2023 in Berlin and headquartered in San Francisco, Nucs AI uses precision medicine to diagnose and treat prostate cancer.
With the number of new cases of prostate cancer worldwide expected to double between 2020 and 2040, the company leverages advanced AI to identify patients most likely to benefit from PSMA-targeted therapies.
PSMA-PET/CT imaging has become the new standard of care for detecting and staging prostate cancer due to its high accuracy compared to conventional imaging methods. PSMA-targeted radiopharmaceuticals are a new type of prostate cancer treatment that uses internal radiation to target prostate cancer cells and can slow or shrink a tumour’s growth.
The company is developing two products designed for clinicians which use prostate-specific membrane antigen (PSMA)-targeted molecular imaging and therapeutics.
DeepPSMA uses discriminative AI to enable fast and reliable detection, staging, and quantification of prostate cancer based on the PSMA-PET/CT images; and SelectPSMA predicts how an individual patient will respond to PSMA-targeted radiopharmaceuticals.
According to Nijat Ahmadov, co-founder and CEO at Nucs AI, the number of radiologists and prostate cancer specialists is not increasing as fast as the number of cases:
“AI is the only technology that can close this gap, giving clinicians more time with patients and maintaining, even improving, the standard of care.
Our SelectPSMA technology is designed to identify those who will respond to PSMA-targeted radiopharmaceuticals such as 177Lu-PSMA-617 (Pluvicto).”
The company will use the funding to further build its platform and support FDA clearance for its technology in North America.
Lead image: Freepik.
Would you like to write the first comment?
Login to post comments